Form 4: Processa Pharmaceuticals Executive David Young Reports Changes in Beneficial Ownership
SEC Form 4 Filing
David Young, President of Research & Development at Processa Pharmaceuticals, reports transactions involving common stock, including acquisition and disposal of shares.
Summary
- On April 1, 2025, David Young, President of Research & Development at Processa Pharmaceuticals, reported changes in his beneficial ownership of the company's common stock.
- He acquired 17,272 shares through the distribution of vested restricted shares.
- He disposed of 5,345 shares at a price of $0.412.
- Following these transactions, Young directly owns 217,332 shares.
- He also has indirect ownership through the Young-Plaisance Revocable Trust (30,985 shares), family entities (10,786 shares), and CorLyst, LLC (18,544 shares).
Sentiment
Score: 5
Explanation: This is a routine regulatory filing. The sentiment is neutral as it simply reports transactions.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of the reported transactions (acquisition and disposal of shares). |
| 04/11/2025 | Date of signature for the Form 4 filing. |
Keywords
beneficial ownership, Processa Pharmaceuticals, David Young, Form 4, common stock, insider trading, vested restricted shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.